Post-earnings recap
Reported
Tue, Mar 12, 2019
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
100%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Despite missing on EPS, Guardant Health's stock rose by 10.75%, indicating investor confidence in the company's future prospects. The management's focus on innovation and market expansion appears to have resonated positively with investors. The lack of revenue data and guidance may leave some uncertainty, but the stock reaction suggests optimism about the company's direction.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.30 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
Management expressed a commitment to growth and innovation in their product lines. They highlighted efforts to strengthen their market position.
We are focused on expanding our market presence and enhancing our product offerings.
Our team remains dedicated to driving innovation in cancer detection.